Skip to main content
. Author manuscript; available in PMC: 2021 Feb 1.
Published in final edited form as: Mol Cancer Ther. 2020 May 19;19(8):1719–1726. doi: 10.1158/1535-7163.MCT-19-1016

Figure 4. Induction of metabolic activity by CDK4/6 and MEK inhibition is functional and can be targeted with an OxPhos inhibitor.

Figure 4.

A OCR of UM001 treated with control (DMSO), MEKi (PD0325901, 5 nM), CDK4/6i (palbociclib, 0.5 μM), or the combination (PD0325901 + palbociclib) (n=3). B as A, but WM3618F cells were utilized. C Incucyte analysis of UM001 and WM3618F cell lines treated with control (DMSO), MEKi (PD0325901, 5 nM), CDK4/6i (palbociclib, 0.5 μM), OxPhosi (IACS-010759, 50 nM), MEKi + CDK4/6i (combo), or MEKi + CDK4/6i + OxPhosi (combo + OxPhosi) (*p=0.05, **p<0.005) (n=3). D Percentage annexin-V positive cells following treatment of UM001 and WM3618F with control (DMSO), MEKi (PD0325901, 5 nM), CDK4/6i (palbociclib, 0.5 μM), OxPhosi (IACS-010759, 50 nM), MEKi + CDK4/6i (combo), or MEKi + CDK4/6i + OxPhosi (combo + OxPhosi) for 48 hours (*p=0.05) (n=3).